Hepatocellular carcinoma (HCC), the fourth leading cause of cancer-related deaths globally, has a 72% mortality rate in Asia. Initially treated with multi-kinase inhibitors, HCC now benefits from expanded immunotherapy options. Multiple myeloma, responsible for 10% of hematologic cancers, is managed with treatments ranging from alkylators and corticosteroids to autologous stem cell transplantation in advanced stages. Staying informed about current treatment strategies and the latest advancements in cancer pharmacotherapy is essential for effective care. To gain detailed insights into “Treatment of Advanced HCC & Multiple Myeloma,” join the reputed Oncologist specialty Dr.
Choo Su Pin & Dr. Fadi Nasr in our exclusive webinar on 26 th March 2026, 8:00 PM IST onwards . Stay tuned!! ##Disclaimer## The content provided on Docplexus is intended for educational purposes only. While we…
